In an interview conducted during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021, Nir Peled, MD, PhD, of Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the updated efficacy and safety results of the Phase 3 KEYNOTE-189 trial. After 4 years of follow-up of over 600 patients with untreated metastatic nonsquamous NSCLC, those who received pembrolizumab exhibited a significant benefit in progression-free and overall survival compared with those who received chemotherapy alone. Dr Peled notes that these benefits were seen regardless of PD-L1 expression.